Hartmut Doehner, MD

Trials

Studies that name Hartmut Doehner, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT04628026 · Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  University of Ulm · recruiting · Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT01477606 · Protocol in Acute Myeloid Leukemia With FLT3-ITD

  University of Ulm · completed · Acute Myeloid Leukemia · principal investigator
• N/A
  NCT01463410 · Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

  Skyline Diagnostics BV · terminated · Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Refractory Anemia With Excess of Blasts (RAEB) · principal investigator
• Ph3
  NCT00893399 · Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

  University of Ulm · completed · Acute Myeloid Leukemia · principal investigator
• Ph1/Ph2
  NCT00850382 · Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

  University of Ulm · completed · Acute Myeloid Leukemia (AML) · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.